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Abstract
Twin gestation contributes significantly to perinatal morbidity and mortality related to high occurrence of preterm birth. We evaluated 202 women consecutively 
selected with twin pregnancies and threatened preterm labor. 98 women were threatened with a single cycle of Atosiban; 34% of them delivered before 34 weeks. The 
study group consisted of 104 patients submitted to a second cycle of Atosiban because of regular uterine contractions and or cervical length modifications occurred 
from 48 hours to 7 days and gestational age was prior to 32 week of gestation (group A). After the second cycle of Atosiban, 49 out of 104 patients received a treatment 
with a vaginal tablet of lactoferrin (group B). After the second cycle of Atosiban, 84% of patients of group A and 90% of patients of group B delivered after 34 weeks. 
The overall rate of delivery before 34 weeks in the studies groups was of 16%. In our experience, repeated cycles of Atosiban have shown effectiveness in delaying 
delivery in twin pregnancies. It seems logical to use an oxytocin receptor antagonist as first line drugs in twin pregnancies because of the increased risk of pulmonary 
edema.
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Introduction
Twin gestation contributes significantly to perinatal morbidity 
and mortality related to high occurrence of preterm birth. Over the 
last decade, the number of assisted-reproduction twins have been 
increasing, doubling the twining rates in Western countries [1]. In 
addition, twin gestations imposed financial and psychological burdens 
on the family and society [2].
In Campania, a Southern region of Italy, the birth rate from assisted 
reproduction increased from 6% in 2007 to 16,5% in 2012.
Overall, the increased risk of maternal and fetal morbidity 
associated with twin compared with singleton pregnancies is nowadays 
the strongest argument for single embriotransfer in the debate of 
assisted reproduction. At least 60% of all twins are born before the 
37th week of gestation. In the last seven years twin gestation in our 
department increased from 3.5% to 7.7% in 2013. In several double 
blind trials Atosiban has demonstrated a tocolytic effectiveness similar 
to beta agonists, with the advantages of no side effects due to its specific 
effect on uterine tissue [3,4]. 
Moreover, women with multiple pregnancy have a higher risk of 
pulmonary edema then women with singleton pregnancy. Pulmonary 
edema occurs in approximately 1/400 women treated with beta-agonists 
[5]. In twin pregnancies, the levels of urinary aldosterone are increased. 
This secondary hyperaldosteronism may be further increased by beta-
agonists, which rise both aldosterone and renin levels. This condition 
induces fluids retention and plasma volume expansion, leading to a 
greater risk of pulmonary edema [5]. 
Prevention of preterm labor is the goal of long-term tocolysis. 
Women with recurrent episodes of recurrent preterm labor are at 
risk for preterm premature rupture of membrane (pPROM), further 
cervical changes and preterm delivery [6]. 
Atosiban has been used in Reproductive Medicine Unit of the 
University of Naples Federico II from 2003 to date, as the first line 
tocolytic drug in women with threatened preterm delivery in twin 
pregnancy. 
We have previously reported our experience in a small series of twin 
pregnancies submitted to a second treatment with Atosiban because 
the presence of symptoms and signs of preterm labor within seven 
days from the first treatment. This therapeutic approach showed to be 
relevant for those patients. On the basis of this preliminary experience, 
we conducted a retrospective cohort study, with the aim to evaluate the 
effectiveness of repeated Atosiban administration in twin pregnancies 
over the last ten years in our single centre. 
Material and methods
This was a retrospective study of twin pregnancies with 276 
consecutive women from April 2003 to December 2013 conducted at 
the Reproductive Medicine Unit of the University of Naples Federico 
II. All women with twin pregnancies with threatened preterm labor 
with or without contractions and reduced cervical length were eligible 
for the study. Exclusion criteria were maternal age <18 years, fetal 
death, major fetal defect, severe twin-to-twin transfusion syndrome or 
selective fetal growth restriction, and cervical length >20mm. On the 
basis of this criteria 74 patients were excluded.
Diagnosis at admission were: 113 preterm labors, 50 preterm 
premature ruptures of membranes, 21 incontinent cervices with 
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cerclage, 18 vaginal bleedings (Figure 1). On the total, 172 twin 
pregnancies derived from reproductive assisted techniques. Preterm 
labor was defined as ≥4 uterine contractions / 30 min and or cervical 
length <20 mm with or without uterine contractions. pPROM was 
proven by a sterile speculum examination (RCOG guidelines N° 
44/2006). Atosiban was administered according to the recommended 
protocol with an initial bolus of 6.75 mg in 1 minute followed by a high 
rate infusion of 18 mg/hour over 3 hours and a lower concentration of 
6 mg/hour over a period of 45 hours.
During the first cycle of Atosiban, all women received corticosteroids 
prophylaxis (antenatal administration of 12 mg of betamethasone, 
followed by a second dose 24 hours later) to enhance lung maturation. 
The second cycle of Atosiban was administered when regular uterine 
contractions and or cervical length modifications occurred from 48 
hours to 7 days after the first cycle and when gestational age was prior 
to 32 weeks of gestation (group A) (Figure 2). Bacterial vaginosis was 
detected in 22% of women and was treated with antibiotic therapy; 
erythromycin (250 mg orally 6 hourly) was given for 10 days following 
the diagnosis of pPROM in all patients. After the second cycle of 
atosiban, 49 out 104 patients received a treatment with a vaginal tablet 
of lactoferrin (Lf) (300 mg) for 21 days (group B) (Figure 3).
98 pregnant women received a single dose of Atosiban just to 
perform the corticosteroids prophilaxis in 48 hours. This group of 
patients (the control group) refers to patients evaluated before our 
preliminary reported experience.
Statistical analysis was performed using GRAPH Pad Prism 4.0 
software (Graph-pad Software Inc, La Jolla, CA). The distribution of 
variables was compared with Student’s Test for paired data. Differences 
associated with p values  lower than 0.05 were considered statistically 
significant. The results are reported as mean +/- standard deviation.
Results
After 48 hours from the end of the first cycle of Atosiban, 98 women 
didn’t show uterine contractions and/or cervical length modifications; 
34% of them delivered before 34 weeks. 
While 104 women had regular uterine contractions and/or cervical 
length modifications (group A). 22% of those patients had recurrent 
symptoms of preterm labor from 48 hours, whereas the remaining 78% 
showed symptoms within 7 days (Figure 3). After the second cycle, 84% 
of patients of group A and 90% of patients of group B delivered after 
34 weeks (Figure 4). No difference was detected between spontaneous 
twin pregnancies and assisted reproduction ones.
The overall mean number of days gained after the start of tocolysis 
was 38 in the group of preterm labor, whereas in the subgroup of 
women with pPROM the interval until delivery was 19 days; in the 
group B the days gained were 52. After initial bolus administration, 
only 5% of women presented drug related side effects such as flushing 
for 1-5 minutes. During infusion, 3% of women experienced side effects 
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Figure 1. Study population characteristics at admission.
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Figure 3. Percentage of patients that respectively showed symptoms of preterm delivery 
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Figure 4. Percentage of patients who delivered <34 weeks in the study groups.
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possibly related to Atosiban such as nausea and vertigo. The overall rate 
of delivery before 34 weeks in the studies groups was of 16%.
Discussion 
In this retrospective study repeated Atosiban administration 
resulted effective in prolonging twin pregnancies. In multiple 
pregnancies, over distension of the uterus with stretching of fetal 
membranes and or cervical ripening is a more likely mechanism for its 
release than infection or inflammation.
The uterine over distension in twin pregnancies may cause a relative 
decidua ischemia with release of lysosomal enzymes. These enzymes 
include several phospholipases which initiate the prostaglandins 
cascade by releasing arachidonic acid, the critical substrate for their 
synthesis. The increased release of prostaglandins affects collagen 
integrity altering the consistence and distensibility of the cervix [7].  
There is an inverse relationship between cervical length and the 
likelihood ratio for preterm birth. Atosiban acts by blocking oxytocin 
receptors. Oxytocin seems to initiate myometrial contractility by both a 
direct and an indirect mechanism. It directly interacts with membrane 
receptors leading to an increase in intracellular calcium. The indirect 
effect of oxytocin is the stimulation of prostaglandins release from 
decidua and fetal membranes; the prostaglandins are strictly involved 
in cervical ripening [8]. 
Recently a Cochrane Database Systematic Review on oxytocin 
receptor antagonists for inhibiting preterm labor underlines the 
importance of well studies about different tocolytic strategies at 
different gestational ages in order to optimize safety and efficacy [9].
Furthermore, Atosiban determined fewer maternal side effects in 
comparison with other tocolytics [9]. As we previously demonstrated 
in a selected group of pregnant from ART, the use of oxytocin receptor 
antagonist in the mid second trimester would appear to be an useful 
tool to delay preterm labour when prostaglandins release activates 
oxytocin receptors [3]. 
Multiple pregnancies are also associated with a major maternal 
plasma volume expansion and secondary hyperaldosteronism [5]. This 
conditions increase the risk of pulmonary edema, particularly when 
tocolytic therapy with beta agonists combined with fluid therapy is 
administered. Beta mimetics increase both aldosterone and renin levels 
in twin pregnancies and may potentiate the risk of pulmonary edema 
[5,10].  
Moreover, same studies revealed that Atosiban is cost-saving 
versus beta mimetics, due to its superior safety profile [4,11]. In our 
experience, repeated cycles of Atosiban have shown effectiveness 
in delaying the interval to delivery, in twin pregnancies. The rate of 
preterm birth < 34week of gestation with single cycle of Atosiban was 
34% (n=33) compared with the overall rate of the studies groups of 
16%. It seems logical to use an oxytocin receptor antagonist as first line 
drugs in twin pregnancies because of the increased risk of pulmonary 
edema.
In addition, the use of vaginal lactoferrin (Lf), an approximately 
80-KDa iron-binding glycoprotein of the transferrin family with 
bacteriostatic and bactericidal properties, was usefull in the maintenance 
therapy, in our experience. Several studies [8,12,13] suggest that Lf plays 
an important role against cervicovaginal inflammation and or infection 
by decreasing levels of interleukin (IL)-6 and increasing cervical length. 
Both drugs, Atosiban and Lf, seem able in preventing preterm delivery 
caused by cervical ripening, blocking prostaglandins release.
Twin pregnancies are at an increased risk of stillbirth, antenatal 
morbidity and infant death. This is largely due to preterm delivery and 
complications of prematurity and low birth weight are the primary 
risk factors for infant mortality. The NICU admission rate was lowest 
following delivery at 38 weeks’ gestation, and the NICU admission rate 
decreased significantly with each additional week of pregnancy from 
32 through 38 weeks’ gestational age. We found an increased risk of 
mortality associated with delivery at 34 weeks’ [14-16]. We hope that 
these data provide information to assist providers for the management 
of threatened preterm labor in twin pregnancies. 
Based on this consideration and the safety profile of Atosiban, two 
cycles are better than one in symptomatic patients before 32 weeks 
of gestation, in our experience, even if corticosteroid prophylaxis 
is already performed This management is used to reduce perinatal 
morbidity/mortality due to extremely prematurity in those twin 
pregnancies with no additional complications that may indicate earlier 
delivery. In addition maintenance therapy using vaginal Lf improve 
gestational age delivery as showed in the study group B.
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